MOV 2 9 7002 PER PRADER ATT

CERTIFICATE OF MAILING

THEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON NOVEMBER 20, 2002

Franziska Reichstein

RECTIVED

DEL 6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600, 2900

Attorney Docket No. FCCC96-11

Applicant:

Tsichlis

Serial No.:

09/202,549

Filed:

October 12, 1999

Group Art Unit No.: 1636

Examiner: Lambertson, D.

For:

Nucleie Acid Molecule For Enhancing Gene Expression

Commissioner for Patents U.S. Patent and Trademark Office Washington, D.C. 20231

RESPONSE TO OFFICE COMMUNICATION OF NOVEMBER 5, 2002

Sir:

This paper is being filed in response to the Office Communication dated November 5, 2002 (Paper No. 24).

This paper is believed timely filed on or before December 5, 2002. Should this paper not be considered timely filed. Applicant hereby requests a retroactive extension of time to file for the number of months required to maintain pendency of the Application. The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 and 1.17 which may be required by this paper to Deposit Account No. 18-0586.

In The Specification:

Please amend the specification as indicated under each of the subheadings below.

Table II

At page 23, please delete Table II, and insert, in place thereof, the substitute paper copy of Table II filed on July 3, 2002. No new matter is added

Sequence Listing

Please substitute the enclosed paper copy sequence listing in place of the paper copy sequence listing now on file in this application. No new matter is added by this amendment.